ICD-10-CM code · FY2027
F14.21 Cocaine dependence, in remission
BillableValid for claims as a specific diagnosis code
About F14.21
EvidencePulse™by 2 Minute Medicine®
Go deeper into cocaine use.
Ask about the latest evidence, the landmark trials or what guidelines recommend, with every study cited. No ads, no sponsored answers.
Coding notes for F14.21
Applicable to Other names for conditions reported with this code.
- Cocaine use disorder, moderate, in early remission
- Cocaine use disorder, moderate, in sustained remission
- Cocaine use disorder, severe, in early remission
- Cocaine use disorder, severe, in sustained remission
Also applies, from F14.2 Cocaine dependence
Excludes1 Not coded here: never report these together with this code (use the code given instead).
Excludes2 Not part of this condition, but a patient can have both: report both codes when both apply.
- cocaine poisoning (T40.5-)
Also applies, from F14 Cocaine related disorders
Excludes2 Not part of this condition, but a patient can have both: report both codes when both apply.
- other stimulant-related disorders (F15.-)
Chapter 5 notes (apply to every code in it)
Includes Conditions this code covers.
- disorders of psychological development
Related codes in F14.2
- F14.20 Cocaine dependence, uncomplicatedBillable
- F14.22 Cocaine dependence with intoxicationHeader
- F14.23 Cocaine dependence with withdrawalBillable
- F14.24 Cocaine dependence with cocaine-induced mood disorderBillable
- F14.25 Cocaine dependence with cocaine-induced psychotic disorderHeader
- F14.28 Cocaine dependence with other cocaine-induced disorderHeader
- F14.29 Cocaine dependence with unspecified cocaine-induced disorderBillable
Latest research on cocaine use
- Transgender veterans may be more likely to use amphetamine, cocaine, and cannabis than cisgender veterans
- Heterogenous pattern of cocaine usage in the United States
- Contingency management programs linked to decreased cocaine use among adults
- Glucagon-like peptide-1 receptor agonists show potential in reducing substance use disorders
- 2 Minute Medicine: Pharma Roundup – Geopolitical instability in the Strait of Hormuz threatens global generic drug supply, daraxonrasib improves pancreatic cancer survival, sparsentan (Filspari) approved for focal segmental glomerulosclerosis, glucagon-like peptide-1 receptor agonists linked to reduced substance use disorders, and orforglipron (Foundayo) expands oral weight loss therapy options
2MM+
Read the research behind every diagnosis
2MM+ gives you every study summary in full, Classics downloads of the landmark trials, EvidencePulse and HypeCheck, and ad-free reading.
See 2MM+ plansICD-10-CM FY2027 code set, as published by the CDC National Center for Health Statistics (NCHS) and CMS, effective October 1, 2026 to September 30, 2027. Codes, titles and notes are shown as published. Check payer rules and the official guidelines before billing. This page is not medical advice.
Get the app